<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211377</url>
  </required_header>
  <id_info>
    <org_study_id>TOTMSEJ1701</org_study_id>
    <nct_id>NCT03211377</nct_id>
  </id_info>
  <brief_title>Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma</brief_title>
  <official_title>Non-interventional Study to Evaluate Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anyang Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anyang Tumor Hospital</source>
  <brief_summary>
    <textblock>
      This is a non-interventional study to observe the safety and efficiency of chemotherapy for
      potentially resectable locally advanced esophagogastric junction
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">April 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival(DFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>time from surgery to disease recurrence or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>time to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AE)</measure>
    <time_frame>through study completion, up to 1 year</time_frame>
    <description>Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 4.03.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Esophagogastric Junction Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant therapy group</arm_group_label>
    <description>Preoperation chemotherapy treatment for patients up to four cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant therapy</arm_group_label>
    <description>Postoperation chemotherapy treatment for patients up to six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perioperative therapy</arm_group_label>
    <description>Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        For this study patients had to be at least 18 years old with histologically or
        cytologically confirmed locally advanced esophagogastric junction cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytological proved locally advanced esophagogastric junction cancer

          -  ECOG performance status ≦2

          -  Stage IIa-IIIc

          -  No distant metastasis (M0)

          -  Sign in Informed Consent Form

        Exclusion Criteria:

          -  History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and Oteracil
             Potassium Capsules , capecitabine, oxaliplatin or the ingredients of this product

          -  Pregnancy or lactation women,

          -  Inadequate hematopoietic function： WBC≦3,500/mm3; ANC≦1,500/mm3; Platelet≦80,000/mm3

          -  Inadequate organ function which is defined as below:

        Total bilirubin &gt;2 pper limit of normal range (ULN); ALT / AST &gt; 2.5 upper limit of normal
        range (ULN); serum creatinine &gt; 1.5 mg/dL, and Ccr &gt; 60 ml/min (estimated by
        Cockcroft-Gault formulation);

          -  Symptomatic peripheral neuropathy

          -  Receiving a concomitant treatment with other fluoropyrimidines

          -  Fluoropyrimidines (DPD) congenital absence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Baozhong</last_name>
    <phone>0372-2923314</phone>
    <email>drlibaozhong@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of science and education</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang , MD</last_name>
      <phone>0372-2923314</phone>
      <email>ayzlyykjk@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

